A comparative proteomics analysis of rat mitochondria from the cerebral cortex and hippocampus in response to antipsychotic medications

Journal of Proteome Research

Volumn 8, Issue 7, 2009, Pages 3633-3641

  Ji, Baohu ^a,b,c   La, Yujuan ^a,b,c   Gao, Linghan ^a,b,c   Zhu, Hui ^a,b,c   Tian, Nan ^a,b,c   Zhang, Ming ^a,b,c   Yang, Yifeng ^a,b,c   Zhao, Xinzhi ^a,b,c,d   Tang, Ruqi ^a,b,c   Ma, Gang ^a,b,c   Zhou, Jian ^a,b,c   Meng, Junwei ^a,b,c   Ma, Jie ^a,b,c   Zhang, Zhao ^a,b,c   Li, Huafang ^e   Feng, Guoyin ^e   Wang, Yujiong ^a   He, Lin ^a,b,c,d   Wan, Chunling ^a,b,c  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^c FUDAN UNIVERSITY   (China)

^d SHANGHAI MENTAL HEALTH CENTER   (China)

^e NINGXIA UNIVERSITY   (China)

Author keywords

Antipsychotic medications; Comparative proteomics; Complex I; Mitochondrial dysfunction; Oxidative phosphorylation; Schizophrenia

Indexed keywords

ADENOSINE TRIPHOSPHATASE; CALMODULIN 1; CHLORPROMAZINE; CLOZAPINE; GLIAL FIBRILLARY ACIDIC PROTEIN; MESSENGER RNA; MITOCHONDRIAL PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE ACTIVATED PROTEIN KINASE 2; NADH DEHYDROGENASE (UBIQUINONE) 1 ALPHA SUBCOMPLEX 10; NADH DEHYDROGENASE (UBIQUINONE) FLAVOPROTEIN 2; NADH DEHYDROGENASE (UBIQUINONE) IRON SULFUR PROTEIN 3; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN 1; PROTEIN ATP5B; PROTEIN ATP6V1A1; PROTEIN ATP6V1B2; PROTEIN C1QBP; PROTEIN CYB5B; PROTEIN TUFM; PROTEIN YWHAH; QUETIAPINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOINFORMATICS; BRAIN CORTEX; BRAIN MITOCHONDRION; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION; HIPPOCAMPUS; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; RAT; RESPIRATORY CHAIN; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; CEREBRAL CORTEX; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HIPPOCAMPUS; MALE; MITOCHONDRIA; OXIDATIVE PHOSPHORYLATION; PHARMACOGENETICS; PHOSPHORYLATION; PROTEOME; PROTEOMICS; RATS; RATS, SPRAGUE-DAWLEY; SCHIZOPHRENIA;

RATTUS;

EID: 67650376532     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr800876z     Document Type: Article

References (51)

1. Thaker, G. K.; Carpenter, W. T., Jr. Advances in schizophrenia. Nat. Med. 2001, 7, 667-71.
2. Mirnics, K.; Middleton, F. A.; Marquez, A.; Lewis, D. A.; Levitt, P. Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron 2000, 28, 53-67.
3. Snyder, E. M.; Murphy, M. R. Schizophrenia therapy: beyond atypical antipsychotics. Nat. Rev. Drug Discovery 2008, 7, 471-72.
4. Freedman, R.; Schizophrenia, N. Engl. J. Med. 2003, 349, 1738-49.
5. Martorell, L.; Segues, T.; Folch, G.; Valero, J.; Joven, J.; Labad, A.; Vilella, E. New variants in the mitochondrial genomes of schizophrenic patients. Eur. J. Hum. Genet. 2006, 14, 520-28.
6. Lieberman, J. A.; Stroup, T. S.; McEvoy, J. P.; Swartz, M. S.; Rosenheck, R. A.; Perkins, D. O.; Keefe, R. S.; Davis, S. M.; Davis, C. E.; Lebowitz, B. D.; Severe, J.; Hsiao, J. K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005, 353, 1209-23.
7. Burkhardt, C.; Kelly, J. P.; Lim, Y. H.; Filley, C. M.; Parker, W. D., Jr. Neuroleptic medications inhibit complex I of the electron transport chain. Ann. Neurol. 1993, 33, 512-17.
8. Modica-Napolitano, J. S.; Lagace, C. J.; Brennan, W. A.; Aprille, J. R. Differential effects of typical and atypical neuroleptics on mitochondrial function in vitro. Arch. Pharm. Res. 2003, 26, 951-59.
9. Maurer, I.; Moller, H. J. Inhibition of complex I by neuroleptics in normal human brain cortex parallels the extrapyramidal toxicity of neuroleptics. Mol. Cell. Biochem. 1997, 174, 255-59.
10. Heiser, P.; Enning, F.; Krieg, J. C.; Vedder, H. Effects of haloperidol, clozapine and olanzapine on the survival of human neuronal and immune cells in vitro. J. Psychopharmacol. 2007, 21, 851-56.
11. Prabakaran, S.; Swatton, J. E.; Ryan, M. M.; Huffaker, S. J.; Huang, J. T.; Griffin, J. L.; Wayland, M.; Freeman, T.; Dudbridge, F.; Lilley, K. S.; Karp, N. A.; Hester, S.; Tkachev, D.; Mimmack, M. L.; Yolken, R. H.; Webster, M. J.; Torrey, E. F.; Bahn, S. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol. Psychiatry 2004, 9, 643.
12. Martins-de-Souza, D.; Gattaz, W. F.; Schmitt, A.; Maccarrone, G.; Hunyadi-Gulyas, E.; Eberlin, M. N.; Souza, G. H.; Marangoni, S.; Novello, J. C.; Turck, C. W.; Dias-Neto, E. Proteomic analysis of dorsolateral prefrontal cortex indicates the involvement of cytoskeleton, oligodendrocyte, energy metabolism and new potential markers in schizophrenia . J. Psychiatr. Res. [Online early access]. DOI: 10.1016/j.jpsychires.2008.11.006. Published online: Dec 23, 2008.
13. Beasley, C. L.; Pennington, K.; Behan, A.; Wait, R.; Dunn, M. J.; Cotter, D. Proteomic analysis of the anterior cingulate cortex in the major psychiatric disorders: Evidence for disease-associated changes. Proteomics. 2006, 6, 3414-25.
14. Sgaragli, G. P.; Valoti, M.; Palmi, M.; Frosini, M.; Giovannini, M. G.; Bianchi, L.; Della Corte, L. Rat tissue concentrations of chlorimipramine, chlorpromazine and their N-demethylated metabolites after a single oral dose of the parent compounds. J. Pharm. Pharmacol 1995, 47, 782-90.
15. Zink, M.; Schmitt, A.; May, B.; Muller, B.; Demirakca, T.; Braus, D. F.; Henn, F. A. Differential effects of long-term treatment with clozapine or haloperidol on GABAA receptor binding and GAD67 expression. Schizophr. Res. 2004, 66, 151-57.
16. Kapur, S.; VanderSpek, S. C.; Brownlee, B. A.; Nobrega, J. N. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J. Pharmacol. Exp. Ther. 2003, 305, 625-31.
17. Douglas, R. M.; Lai, J. C.; Bian, S.; Cummins, L.; Moczydlowski, E.; Haddad, G. G. The calcium-sensitive large-conductance potassium channel (BK/MAXI K) is present in the inner mitochondrial membrane of rat brain. Neuroscience 2006, 139, 1249-61.
18. Pastorelli, R.; Carpi, D.; Campagna, R.; Airoldi, L.; Pohjanvirta, R.; Viluksela, M.; Hakansson, H.; Boutros, P. C.; Moffat, I. D.; Okey, A. B.; Fanelli, R. Differential expression profiling of the hepatic proteome in a rat model of dioxin resistance: correlation with genomic and transcriptomic analyses. Mol. Cell. Proteomics 2006, 5, 882-94.
19. Munakata, K.; Iwamoto, K.; Bundo, M.; Kato, T. Mitochondrial DNA 3243A>G mutation and increased expression of LARS2 gene in the brains of patients with bipolar disorder and schizophrenia. Biol. Psychiatry 2005, 57, 525-32.
20. Yan, S. P.; Zhang, Q. Y.; Tang, Z. C.; Su, W. A.; Sun, W. N. Comparative proteomic analysis provides new insights into chilling stress responses in rice. Mol. Cell. Proteomics 2006, 5, 48496].
21. Ben Shachar, D.; Karry, R. Sp1 expression is disrupted in schizophrenia; a possible mechanism for the abnormal expression of mitochondrial complex I genes, NDUFV1 and NDUFV2. PLoS One 2007, 2, e817.
22. Balijepalli, S.; Boyd, M. R.; Ravindranath, V. Inhibition of mitochondrial complex I by haloperidol: the role of thiol oxidation. Neuropharmacology 1999, 38, 567-77.
23. Barrientos, A.; Marin, C.; Miro, O.; Casademont, J.; Gomez, M.; Nunes, V.; Tolosa, E.; Urbano-Marquez, A.; Cardellach, F. Biochemical and molecular effects of chronic haloperidol administration on brain and muscle mitochondria of rats. J. Neurosci. Res. 1998, 53, 475-81.
24. Prince, J. A.; Blennow, K.; Gottfries, C. G.; Karlsson, I.; Oreland, L. Mitochondrial function is differentially altered in the basal ganglia of chronic schizophrenics. Neuropsychopharmacology 1999, 21, 372-79.
25. Whatley, S. A.; Curti, D.; Das, Gupta, F.; Ferrier, I. N.; Jones, S.; Taylor, C.; Marchbanks, R. M. Superoxide, neuroleptics and the ubiquinone and cytochrome b5 reductases in brain and lymphocytes from normals and schizophrenic patients. Mol. Psychiatry 1998, 3, 227-37.
26. Karry, R.; Klein, E.; Ben Shachar, D. Mitochondrial complex I subunits expression is altered in schizophrenia: a postmortem study. Biol. Psychiatry 2004, 55, 676-84.
27. Ben Shachar, D.; Zuk, R.; Glinka, Y. Dopamine neurotoxicity: inhibition of mitochondrial respiration. J. Neurochem. 1995, 64, 718-23.
28. Berman, S. B.; Hastings, T. G. Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. J. Neurochem. 1999, 73, 1127-37.
29. Chan, P.; Di Monte, D. A.; Luo, J. J.; DeLanney, L. E.; Irwin, I.; Langston, J. W. Rapid ATP loss caused by methamphetamine in the mouse striatum: relationship between energy impairment and dopaminergic neurotoxicity. J. Neurochem. 1994, 62, 2484-87.
30. Cohen, G.; Farooqui, R.; Kesler, N. Parkinson disease: a new link between monoamine oxidase and mitochondrial electron flow. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 4890-94.
31. Przedborski, S.; Jackson-Lewis, V.; Muthane, U.; Jiang, H.; Ferreira, M.; Naini, A. B.; Fahn, S. Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity. Ann. Neurol. 1993, 34, 715-23.
32. Belogrudov, G.; Hatefi, Y. Catalytic sector of complex I (NADH: ubiquinone oxidoreductase): subunit stoichiometry and substrate-induced conformation changes. Biochemistry 1994, 33, 4571-76.
33. Ben Shachar, D. Mitochondrial dysfunction in schizophrenia: a possible linkage to dopamine. J. Neurochem. 2002, 83, 1241-51.
34. Blass, J. P. Glucose/mitochondria in neurological conditions. Int. Rev. Neurobiol. 2002, 51, 325-76.
35. Maurer, I.; Zierz, S.; Moller, H. Evidence for a mitochondrial oxidative phosphorylation defect in brains from patients with schizophrenia. Schizophr. Res. 2001, 48, 125-36.
36. Whatley, S. A.; Curti, D.; Marchbanks, R. M. Mitochondrial involvement in schizophrenia and other functional psychoses. Neurochem. Res. 1996, 21, 995-1004.
37. Mulcrone, J.; Whatley, S. A.; Ferrier, I. N.; Marchbanks, R. M. A study of altered gene expression in frontal cortex from schizophrenic patients using differential screening. Schizophr. Res. 1995, 14, 203-13.
38. Ben Shachar, D.; Bonne, O.; Chisin, R.; Klein, E.; Lester, H.; Aharon-Peretz, J.; Yona, I.; Freedman, N. Cerebral glucose utilization and platelet mitochondrial complex I activity in schizophrenia: A FDG-PET study. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31, 807-13.
39. Ben Shachar, D.; Zuk, R.; Gazawi, H.; Ljubuncic, P. Dopamine toxicity involves mitochondrial complex I inhibition: implications to dopamine-related neuropsychiatric disorders. Biochem. Pharmacol. 2004, 67, 1965-74.
40. Kung, L.; Roberts, R. C. Mitochondrial pathology in human schizophrenic striatum: a postmortem ultrastructural study. Synapse 1999, 31, 67-75.
41. Fattal, O.; Budur, K.; Vaughan, A. J.; Franco, K. Review of the literature on major mental disorders in adult patients with mitochondrial diseases. Psychosomatics 2006, 47, 1-7.
42. Iwamoto, K.; Bundo, M.; Kato, T. Altered expression of mitochondria-related genes in postmortem brains of patients with bipolar disorder or schizophrenia, as revealed by large-scale DNA microarray analysis. Hum. Mol. Genet. 2005, 14, 241-53.
43. Shao, L.; Vawter, M. P. Shared gene expression alterations in schizophrenia and bipolar disorder. Biol. Psychiatry 2008, 64, 89-97.
44. Paulson, L.; Martin, P.; Nilsson, C. L.; Ljung, E.; Westman-Brinkmalm, A.; Blennow, K.; Davidsson, P. Comparative proteome analysis of thalamus in MK-801-treated rats. Proteomics. 2004, 4, 819-25.
45. Martins-de-Souza, D.; Gattaz, W. F.; Schmitt, A.; Rewerts, C.; Marangoni, S.; Novello, J. C.; Maccarrone, G.; Turck, C. W.; Dias-Neto, E. Alterations in oligodendrocyte proteins, calcium homeostasis and new potential markers in schizophrenia anterior temporal lobe are revealed by shotgun proteome analysis. J. Neural. Transm. 2009, 116, 275-89.
46. Peerschke, E. I.; Murphy, T. K.; Ghebrehiwet, B. Activation-dependent surface expression of gC1qR/p33 on human blood platelets. Thromb. Haemostasis 2003, 89, 331-39.
47. Webster, M. J.; O'Grady, J.; Kleinman, J. E.; Weickert, C. S. Glial fibrillary acidic protein mRNA levels in the cingulate cortex of individuals with depression, bipolar disorder and schizophrenia. Neuroscience 2005, 133, 453-61.
48. Culbert, A. A.; Skaper, S. D.; Howlett, D. R.; Evans, N. A.; Facci, L.; Soden, P. E.; Seymour, Z. M.; Guillot, F.; Gaestel, M.; Richardson, J. C. MAPK-activated protein kinase 2 deficiency in microglia inhibits pro-inflammatory mediator release and resultant neurotoxicity. Relevance to neuroinflammation in a transgenic mouse model of Alzheimer disease. J. Biol. Chem. 2006, 281, 23658-67.
49. Valente, L.; Tiranti, V.; Marsano, R. M.; Malfatti, E.; Fernandez-Vizarra, E.; Donnini, C.; Mereghetti, P.; De Gioia, L.; Burlina, A.; Castellan, C.; Comi, G. P.; Savasta, S.; Ferrero, I.; Zeviani, M. Infantile encephalopathy and defective mitochondrial DNA translation in patients with mutations of mitochondrial elongation factors EFG1 and EFTu. Am. J. Hum. Genet. 2007, 80, 44-58.
50. Paulson, L.; Martin, P.; Persson, A.; Nilsson, C. L.; Ljung, E.; Westman-Brinkmalm, A.; Eriksson, P. S.; Blennow, K.; Davidsson, P. Comparative genome- and proteome analysis of cerebral cortex from MK-801-treated rats. J. Neurosci. Res. 2003, 71, 526-33.
51. Pradet-Balade, B.; Boulme, F.; Beug, H.; Mullner, E. W.; Garcia-Sanz, J. A. Translation control: bridging the gap between genomics and proteomics. Trends Biochem. Sci. 2001, 26, 225-29.